Podcasts about Cardiology

Another ESC recap, listener feedback on two trials, and a paper on GLP-1 effects on inflammation from the SELECT trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Correction on PROFID Trial II Listener Feedback III Fifth Universal Definition of MI Fifth Universal Definition of MI https://doi.org/10.1093/eurheartj/ehag101 Foy/Mandrola Editorial on Troponin Use and Interpretation https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2777967 IV New ESC HF Guidelines ESC Guidelines for Management of HF https://doi.org/10.1093/eurheartj/ehag100 Sanjay Kaul on X https://x.com/kaulcsmc/status/2094959683215958158?s=20 Geographic Disparities in TOPCAT https://pmc.ncbi.nlm.nih.gov/articles/PMC5065247/ V AIR STEMI Trial AIR-STEMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2605373 CR Strategies After MI https://www.jacc.org/doi/10.1016/j.jacc.2024.04.051 PRAMI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1305520 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 VI GLP-1 News – A SELECT Trial Secondary Analysis Semaglutide and hsCRP in Patients with CVD and Obesity https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.074482 The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we note and mourn the passing of pediatric cardiologist and thought leader Dr. Steven Lipshultz who passed on September 4, 2026. Dr. Lipshultz was one of the most significant cardiologists of the past half century and his contributions to the fields of pediatric cardiomyopathy, HIV cardiomyopathy and cardio-oncology were gigantic and meaningful. This week we turn back the clock and review a landmark work of Dr. Lipshultz from the Pediatric Cardiomyopathy Registry that was published in 2003 in the NEJM and we speak with 3 pediatric cardiomyopathy experts as well as friends and colleagues of Dr. Lipshultz - namely Dr. Neha Bansal of NYU, Dr. Daphne Hsu of the Albert Einstein College of Medicine and Dr. Joseph Rossano of the Children's Hospital of Philadelphia. Each shares their remembrances of this work and provide insights into the legacy of Dr. Lipshultz. doi: 10.1056/NEJMoa021715.

In this episode, Jeffrey Marshall, MD, Chief of Cardiology at the Northside Hospital Heart Institute, joins the podcast to reflect on defining moments throughout his career and the evolution of cardiology at Northside. He also shares how his role has changed over time and offers his perspective on the growing attention surrounding artificial intelligence, including why he believes AI may be overhyped by the media.

Welcome to the latest Midlife Minute. This episode unpacks ongoing research on Lp(a), explores how women's lipids change during the perimenopause-to-menopause transition, and clarifies what we can do about it. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: How total cholesterol, LDL, and ApoB tend to rise most steeply around the final menstrual period, rather than increasing gradually with chronological aging Why women should have their Lp(a) checked both before and after menopause How oral and transdermal estradiol can affect LDL, HDL, triglycerides, and Lp(a) differently Why I recommend including ApoB when checking your lipids during the perimenopause window How your lifestyle can reduce your cardiovascular risk, even when your Lp(a) is elevated Why omega-3 fatty acids and commonly used lipid medications do not lower Lp(a) Why supplements are not replacements for statins in genuinely high-risk patients  I review the various PCSK9 inhibitors currently available, how they are administered, and their effects  How a CAC, a CT angiogram, and an AI-assisted CT angiogram can help women and their providers determine how aggressive their approach should be when Lp(a) is elevated Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association.Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline 2. Menopause: A Cardiometabolic Transition. The Lancet. Diabetes & Endocrinology. 2022. Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T.Review 3. Dyslipidemia Across the Menopause Transition: Mechanisms, Trajectories, and Opportunities for Cardiovascular Prevention. Maturitas. 2026. Castaneda R, Tatit CP, Hurtado Andrade MD, Faubion SS, Shufelt CL.RecentReview 4. Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML. 5. Lipid Metabolism in Women: A Review. Atherosclerosis. 2025. van Oortmerssen JAE, Mulder JWCM, Kavousi M, Roeters van Lennep JE.Review 6. Are Changes in Cardiovascular Disease Risk Factors in Midlife Women Due to Chronological Aging or to the Menopausal Transition?. Journal of the American College of Cardiology. 2009. Matthews KA, Crawford SL, Chae CU, et al.Observational 7. Trajectories of Lipids Around the Menopause Transition in Chinese Women: Results of the Kailuan Cohort Study. Fertility and Sterility. 2023. Dai Q, Wu S, Cao Z, et al. 8. Lipid Management in Patients With Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. 2020. Newman CB, Blaha MJ, Boord JB, et al.Guideline 9. The Effects of Menopause Hormone Therapy on Lipid Profile in Postmenopausal Women: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology. 2022. Nie G, Yang X, Wang Y, et al.SR 10. Perspectives on Dyslipidemia and Coronary Heart Disease in Women. Journal of the American College of Cardiology. 2005. Bittner V.Review 11. Dyslipidemia in Midlife Women: Approach and Considerations During the Menopausal Transition. Maturitas. 2022. Torosyan N, Visrodia P, Torbati T, Minissian MB, Shufelt CL.Review 12. Effects of gender, age and menopausal status on serum apolipoprotein concentrations.13.Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg     14. Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications. Diabetes, Obesity & Metabolism. 2025. Razavi AC, Bhatia HS, Blumenthal RS, Shapiro MD, Mehta A.RecentReview 15. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. Journal of the American College of Cardiology. 2021. Cicero AFG, Fogacci F, Zambon A.Review 16. Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Drugs. 2023. Blais JE, Huang X, Zhao JV.SR 17. Non-Genetic Influences on Lipoprotein(a) Concentrations. Atherosclerosis. 2022. Enkhmaa B, Berglund L.Review 18. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. Journal of the American College of Cardiology. 2018. Tsimikas S, Fazio S, Ferdinand KC, et al.Review 19. Consumption of a defined, plant‐based diet reduces lipoprotein(a), inflammation, and other atherogenic lipoproteins and particles within 4 weeks. Clinical Cardiology. 2018. Najjar RS, Moore CE, Montgomery BD. 20. Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies. Clinical Therapeutics. 2019. Santos HO, Kones R, Rumana U, et al.Review 21. Effect of Lipid-Lowering Therapies on Lipoprotein(a) Levels: A Comprehensive Meta-Analysis of Randomized Controlled Trials. Atherosclerosis. 2025. Xie S, Galimberti F, Olmastroni E, et al.Recent 22. Effect of Omega-3 Fatty Acid Supplementation on the Postprandial Metabolism of Apolipoprotein(a) in Familial Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis. 2023. Ying Q, Croyal M, Chan DC, et al.RCT 23.Lipoprotein(a) and Cardiovascular Disease. Lancet. 2024. Nordestgaard BG, Langsted A.Review 24. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022. Reyes-Soffer G, Ginsberg HN, Berglund L, et al.Guideline 25.Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3.Journal of the American College of Cardiology. 2023. Malick WA, Goonewardena SN, Koenig W, Rosenson RS.Review 26.2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American Collegeof Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026. Writing Committee Members, Blumenthal RS, Morris PB, et al.Guideline 27. Noninvasive Coronary Atherosclerotic Plaque Imaging. JACC. Cardiovascular Imaging. 2023. Kwiecinski J, Tzolos E, Williams MC, et al.Review 28. Computed Tomography Angiography Versus Agatston Score for Diagnosis of Coronary Artery Disease in Patients With Stable Chest Pain: Individual Patient Data Meta-Analysis of the International COME-CCT Consortium. European Radiology. 2022. Wieske V, Walther M, Dubourg B, et al.SR 29. Association of Coronary Artery Calcium Score With Qualitatively and Quantitatively Assessed Adverse Plaque on Coronary CT Angiography in the SCOT-HEART Trial. European Heart Journal. Cardiovascular Imaging. 2022. Osborne-Grinter M, Kwiecinski J, Doris M, et al.Clinical Trial 30. AI-Guided Quantitative Plaque Staging Predicts Long-Term Cardiovascular Outcomes in Patients at Risk for Atherosclerotic CVD. JACC. Cardiovascular Imaging. 2024. Nurmohamed NS, Bom MJ, Jukema RA, et al.Observational 31. The Lancet Commission on Rethinking Coronary Artery Disease: Moving From Ischemia to Atheroma. Lancet. 2025. Zaman S, Wasfy JH, Kapil V, et al.Review 32. Efficacy and safety of novel lipoprotein(a)‐targeted therapies: A systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity & Metabolism. 2026. Santana AUL, Yusufzai MO, Freitas APS, et al. Recent Opinion

Join Alison Stephens, PA-C, as she defines PSVT (paroxysmal supraventricular tachycardia), explores its impact on patients' quality of life, and discusses various treatment options, including a new FDA-approved nasal spray.CE units are available for this episode only through June 15, 2027. To access CE, visit pcna.net/course/spotlight-on-psvt/.Related PCNA Resources:​​- Patient Journey: PSVT Strikes Anytime, Anyplace - https://pcna.net/resource/patient-journey-psvt-strikes-anytime-anyplace-video/​- PSVT: Barriers and Solutions to the Disease Burden for Patients - https://pcna.net/resource/psvt-barriers-and-solutions-to-the-disease-burden-for-patients/- Living with PSVT: A Patient-Centered Care Plan ​- Living with PSVT: Episodic Rapid Heart Rates - https://pcna.net/podcast/living-with-psvt-a-patient-centered-care-plan/Related Episode Resources:- Self-Administered Etripamil and Emergency Department Visits in Supraventricular Tachycardia - https://jamanetwork.com/journals/jamacardiology/fullarticle/2832045- Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00776-6/fulltext- Catheter Ablation of Atypical Atrioventricular Nodal Reentrant Tachycardia - https://pubmed.ncbi.nlm.nih.gov/27754882/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This podcast episode explores transitions of care for patients with PSVT (paroxysmal supraventricular tachycardia), featuring insights from Alison Stephens, PA-C and Todd Wagner, RN. They discuss diagnosis, treatment pathways and the importance of patient education, follow-up care, and addressing social determinants of health to prevent recurrence and improve outcomes. CE units are available for this episode only through June 15, 2027. To access CE, visit pcna.net/course/spotlight-on-psvt/.Related PCNA Resources​​- Patient Journey: PSVT Strikes Anytime, Anyplace - https://pcna.net/resource/patient-journey-psvt-strikes-anytime-anyplace-video/​- PSVT: Barriers and Solutions to the Disease Burden for Patients - https://pcna.net/resource/psvt-barriers-and-solutions-to-the-disease-burden-for-patients/​- Living with PSVT: A Patient-Centered Care Plan - https://pcna.net/podcast/living-with-psvt-a-patient-centered-care-plan/​- Living with PSVT: Episodic Rapid Heart Rates - https://pcna.net/podcast/living-with-psvt-episodic-rapid-heart-rates-psvt-afib-and-more/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Your primary care provider is doing their best. But there's something they may not be telling you — not because they're hiding it, but because they simply can't know everything.In this episode of Your Health University, Jamie Preston sits down with Scott Middleton — Founder and Chief Disruption Officer of Your Health — to talk about one of the most underutilized parts of the American healthcare system: specialty care. Scott shares real stories from the field that will make you rethink what you expect from your next appointment, including a patient who had been living in a nursing home for years without ever being offered a weight-loss medication that was available to her, and a lawsuit that turned on a single chest x-ray that no one thought to order.What you'll learn in this episode:Why your primary care provider legally cannot keep up with every new medication, treatment, and specialist recommendation — and what to do about itWhat GLP-1 medications are, who qualifies, and why so many eligible patients are never told they existThe standard of care around lung cancer screening for smokers — and why not knowing this can have life-altering consequencesHow to ask for a specialist referral (and what happens if your provider pushes back)Why behavioral health is one of the most under-accessed specialties in America — and how to change that for yourselfWhat "integrated care" actually looks like when it works — and what you deserve to expect from your healthcare teamYou are the CEO of your own health. This episode gives you tools to act like it. www.YourHealth.Org

Most healthcare organizations know specialty care matters. Almost none of them are actually using it at the level their patients need.In this episode of The Disrupted Podcast, Jamie Preston sits down with Scott Middleton — Founder and Chief Disruption Officer of Your Health — for an unfiltered look at one of the most critical gaps in care delivery: specialty services. Your Health currently routes about 10% of its patient appointments through specialty providers. The national average is 20%. Scott makes the case — with real stories from nursing homes, lawsuits, and the road across South Georgia — that closing that gap isn't just a clinical priority, it's a survival strategy.What you'll hear in this episode:Why a 400-pound patient in a nursing home had never been offered a GLP-1 for weight loss — and what that reveals about how providers think about specialtyThe exact communication chain (DPH → EDCS → Care Manager → Provider) and precisely where it breaks downHow 80% of Your Health patients have behavioral health needs while psych providers sit with open schedules — and how to fix that paradoxWhy texts and emails don't cut it in care coordination — and why voice-to-voice is the only real standardThe lawsuit that should have been prevented with a single chest x-ray, and what it means for provider accountability going forwardWhy Scott banned the word "no" inside Your Health — and the mindset shift that comes with replacing itSpecialty is what separates Your Health from every other provider in the market. If you're a DPH, a care manager, or a provider inside this system — this episode is for you. If you're a healthcare leader watching specialty care fall through the cracks anywhere, it might be for you too. www.YourHealth.Org

A second ESC recap plus two breaking stories on the failure of an investigational Lp(a) reducing drug and a new FDA approval of an AI-ECG app are covered by John Mandrola, MD This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Lp(a) Disappointment HORIZON https://clinicaltrials.gov/study/NCT04023552 Press Release https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd Rationale paper https://doi.org/10.1016/j.ahj.2025.03.019 II FDA Clears AI-ECG for Acute MI Detection  Accuracy of cath lab activation decisions for STEMI-equivalent and mimic ECGs: Physicians vs. AI (Queen of Hearts by PMcardio) 10.1016/j.ajem.2025.07.061 AI-Enabled ECG Analysis Improves Diagnostic Accuracy and Reduces False STEMI Activations: A Multicenter U.S. Registry https://www.jacc.org/doi/10.1016/j.jcin.2025.10.018 Queen of Hearts™ AI ECG App https://www.powerfulmedical.com/pmcardio-stemi/ III TARGET CTCA Trial Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain https://www.nejm.org/doi/10.1056/NEJMoa2608903 IV CorCal trial Press release https://www.escardio.org/news/press/press-releases/new-data-presented-on-the-use-of-coronary-artery-calcium-for-cardiovascular-risk-assessment/ CorCal Outcomes: A randomized trial using the pooled cohort equation or coronary artery calcium to select statin therapy in primary prevention patients. Study design and baseline characteristics https://doi.org/10.1016/j.ahj.2026.107473 V AMUNDSEN Trial LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial InfarctionThe AMUNDSEN Randomized Clinical Trial https://jamanetwork.com/journals/jama/fullarticle/2853274 VI TRIC-I-HF trial Tricuspid Repair Cuts Death, HF Hospitalization in Severe TR https://www.medscape.com/viewarticle/tricuspid-repair-cuts-death-hf-hospitalization-severe-tr-2026a1000wvk Tricuspid-Valve Intervention in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa2606934 You May Also Like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington  Questions or feedback, please contact news@medscape.net

This week we review a recent work assessing the impact of birth day of the week on neurological outcomes amongst newborns undergoing CHD surgery. Why might certain days of the week be associated with higher degrees of white matter injury in the brain of newborns who have had congenital heart surgery? What are the potential mechanisms for this? What might be the unintended consequences of ‘controlling' birth day of the week? We speak with the Associate Division Chief for Research within the Division of Cardiac Anesthesiology at Children's Hospital of Philadelphia and author of this week's work, Dr. Jennifer Lynch.  DOI: 10.1016/j.xjon.2026.101700

Welcome to the latest Midlife Minute. Today, I'm answering listeners' questions about cardiovascular risk, focusing on Lp(a), LDL, statins, and the changes women experience after menopause. Stay tuned for more! IN THIS EPISODE, YOU WILL LEARN: Why women should have their Lp(a) checked both before and after menopause How Lp(a) works as a risk enhancer, and how cardiovascular risk becomes more significant when elevated Lp(a) occurs alongside high LDL Why family history is particularly helpful for women with a 10-year calculated cardiovascular risk that looks reassuringly low I review the current guidelines for primary prevention Why, even though research has shown reductions in major cardiac events with GLP-1s, GLP-1s do not replace statins for lowering LDL  What a CAC score can reveal about coronary artery calcification, and what it cannot detect How AI-assisted CT angiography (such as Clearly) can map, quantify, and characterize plaque throughout the coronary branches Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com  Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow.  Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line References: 1.  ​Lipoprotein(a) and Women's Cardiovascular Health: A Review. JACC. Advances. 2026. Michos ED, Saucier S, Mehran R, Koschinsky ML.Recent 2.  ​Sex Differences of Lipoprotein(a) Levels and Associated Risk of Morbidity and Mortality by Age: The Copenhagen General Population Study. Atherosclerosis. 2022. Simony SB, Mortensen MB, Langsted A, et al. 3. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2022. Stone NJ, Smith SC, Orringer CE, et al.Review 4. Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). JAMA Cardiology. 2026. Nordestgaard AT, Chasman DI, Moorthy V, et al.RecentObservational 5.  ​Lipoprotein(a).The Journal of the American Medical Association. 2025. Mora S, Kronenberg  6. Clinical Practice Guideline on Lipid Management for Cardiovascular Disease Risk Reduction. Department of Veterans Affairs (2026). 2026. Paul Heidenreich, Lance Spacek, Neil Gregor, et al. Guideline 7. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. Journal of the American College of Cardiology. 2020. Mehta A, Virani SS, Ayers CR, et al.Observational 8. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2010. Greenland P, Alpert JS, Beller GA, et al.Guideline 9. Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women. The Journal of the American Medical Association. 2016. Kavousi M, Desai CS, Ayers C, et al.SR 10. ​Coronary Artery Calcium Scores and Risk for Cardiovascular Events in Women Classified as “Low Risk” Based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA). Archives of Internal Medicine. 2007. Lakoski SG, Greenland P, Wong ND, et al.Observational 11. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019. Arnett DK, Blumenthal RS, Albert MA, et al.Guideline 12. HOPE for Rational Statin Allocation for Primary Prevention: A Coronary Artery Calcium Picture Is Worth 1000 Words. Mayo Clinic Proceedings. 2020. Orringer CE, Maki KC.Review 13. Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2020. Cho L, Davis M, Elgendy I, et al.Review 14. Health Maintenance in Postmenopausal Women. American Family Physician. 2025. Plesa M, Wong A, Katsaggelos E.Guideline 15.  ​Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care. 2024. Lingvay I, Deanfield J, Kahn SE, et al.RCT 16.  ​Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. 2023. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.RCT 17. Long-Term Weight Loss Effects of Semaglutide in Obesity Without Diabetes in the SELECT Trial. Nature Medicine. 2024. Ryan DH, Lingvay I, Deanfield J, et al.RCT 18. Interventions for the Prevention and Management of Cardiometabolic Multiple Long-Term Conditions. Lancet. 2026. Valabhji J, Hope D, Sayed NE, et al.RecentReview 19. Glucagon‐Like Peptide‐1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta‐Analysis of Randomized‐Controlled Trials. Clinical Cardiology. 2024. Hosseinpour A, Sood A, Kamalpour J, et al.SR 20. ​FDA Orange Book. FDA Orange Book. 2026. 21. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026. American Diabetes Association Professional Practice Committee for Diabetes*.RecentGuideline 22. Premature Coronary Artery Disease in Women: Sex-Specific Risk Factors, Pathogenetic Mechanisms and Clinical Implications. Annals of Medicine. 2026. Li F, Hong D, Yang M, et al.RecentReview 23. Cardiovascular Disease Risk Factors in Women: The Impact of Race and Ethnicity: A Scientific Statement From the American Heart Association. Circulation. 2023. Mehta LS, Velarde GP, Lewey J, et al.Guideline 24. Preventing CVD in Women: Common Questions and Answers. American Family Physician. 2023. Westfall E, Viere AB, Genewick JE.Review 25. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation. 2020. El Khoudary SR, Aggarwal B, Beckie TM, et al.Guideline

Uncontrolled and resistant hypertension is more common than we think. In the second episode of this special three-part series, Dr. Neil Skolnik discusses management strategies, but also explores our new understanding of aldosterone and its stealth role in hypertension. This series is supported with support from AstraZeneca. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to DOC Updates via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Payal Kohli, MD, Harvard-educated preventive cardiologist and the Founder and Medical Director of Cherry Creek Heart​ in Aurora Colorado, Associate Adjunct Professor in Cardiology at Johns Hopkins University, and Associate Adjunct Professor in Cardiology at Duke University Selected references: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee. Hypertension 2025; 82(10) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016;387:957 Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med 2025;393:1363-74. DOI: 10.1056/NEJMoa2507109 Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, 2025, 00, 1–43 https://doi.org/10.1210/clinem/dgaf284 A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373:2103-2116

ESC recaps on the SINGLE-AF trial, CMR Guide trial, two ATTR studies, PVI-SHAM-AF, STAREE, and an observational study of ICD benefit over the past decades are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I SINGLE-AF Trial To Anticoagulate or Not in Intermediate-Risk AF: The SINGLE-AF Trial https://www.medscape.com/viewarticle/anticoagulate-or-not-intermediate-risk-af-single-af-trial-2026a1000uko SINGLE-AF https://www.nejm.org/doi/10.1056/NEJMoa2607978 II Scar as an ICD risk stratifier Is Scar on CMR an Indication for ICD? CMR Guide Leaves Doubts https://www.medscape.com/viewarticle/scar-cmr-indication-icd-cmr-guide-leaves-doubts-2026a1000ukq CMTR GUIDE Trial https://jamanetwork.com/journals/jama/fullarticle/2853395 MADIT II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa013474 III Single vs Dual Therapy in ATTR-CM HELIOS-B Trial Sub-analysis https://www.sciencedirect.com/science/article/pii/S0735109726072086 HELIOS-B Sub-analysis Editorial https://www.sciencedirect.com/science/article/pii/S0735109726073766#bib8 HELIOS-B main trial https://www.nejm.org/doi/10.1056/NEJMoa2409134 CARDIO-TTRansform Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2608510 IV A Stunning Result of another Sham-controlled AF ablation trial Does AF Ablation Work? That's in Question After PVI-SHAM-AF https://www.medscape.com/viewarticle/does-af-ablation-work-s-question-after-sham-pvi-af-2026a1000uli PVI-SHAM-AF Trial 10.1016/S0140-6736(26)01558-8 External Link SHAM-PVI Trial https://jamanetwork.com/journals/jama/fullarticle/2823283 PFA-Sham Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079484 V Should Older Adults Take Statins: The STAREE trial. STAREE Strengthens Case for Over-the-Counter Statins https://www.medscape.com/viewarticle/staree-strengthens-case-over-counter-statins-2026a1000vrw STAREE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2607314 VII Declining ICD Benefit After MI   Mortality Reduction with ICD for Prevention of SCD Post-MI  https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag706/8768943  CONTEMP-ICD Trial https://clinicaltrials.gov/study/NCT06543446  PROFID-EHRA Trial https://profid-project.eu/profid-ehra-trial/  The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This Week In Startups is made possible by: Odoo - http://Odoo.com/twist Northwest Registered Agent - https://www.northwestregisteredagent.com/twistdomain Rippling - http://Rippling.ai/twist Today's show: Your doctor almost certainly isn't testing your insulin. Dr. Mark Hyman sits down with Jason to explain the broken system that Function is fixing, and what 100 million biomarkers say about how sick America actually is. Learn why insulin beats blood sugar as an early warning for TKTKTK. Why might "normal" lab ranges be unreliable? PLUS, how does an expert like Dr. Hyman feel about GLP-1s and psychedelics? Guests: Dr. Mark Hyman on X: https://x.com/drmarkhyman Function: https://www.functionhealth.com/ Relevant Links: The Dr. Hyman Show — https://podcasts.apple.com/us/podcast/the-dr-hyman-show/id1382804627 Function pricing — https://www.functionhealth.com/pricing Ezra — the full-body MRI company Function acquired https://ezra.com/ Galleri (GRAIL) — the multi-cancer early detection blood test — https://www.galleri.com/ Tufts / JACC study — the source of the "93% of Americans have metabolic dysfunction" — https://now.tufts.edu/2022/07/05/only-7-american-adults-have-good-cardiometabolic-health American College of Cardiology — https://www.acc.org/ Dr. Jorge Plutzky — https://www.health.harvard.edu/authors/jorge-plutzky-md OpenEvidence — https://www.openevidence.com/ Stanford Metabolic Psychiatry Clinic — https://med.stanford.edu/news/all-news/2022/11/metabolic-psychiatry.html Stanford Medicine on the ibogaine findings → https://med.stanford.edu/news/all-news/2024/01/ibogaine-ptsd.html Texas SB 2308 — the $50M state investment in ibogaine trials — https://www.texastribune.org/2026/03/31/texas-ibogaine-research-clinical-trials-psychedelics/ Timestamps: 0:00 What Function actually is 6:43 Healthspan vs. sick care 10:16 Odoo - The all-in-one business platform. Your first app is free! Get started today at https://Odoo.com/twist 11:32 A $300 vitamin D test vs. a $10 one 18:08 Should a 25-year-old get a whole-body MRI? 20:42 Northwest Registered Agent - Got a new business idea? Northwest Registered Agent helps you bring it to life. Get a free domain, email, phone number, and more - with no purchase required! Learn more at https://www.northwestregisteredagent.com/twistdomain 24:23 Why medicine is still running on paper 25:41 The study where the chatbot beat the doctors 27:02 micro1, doctors in the loop, and why AI still needs guardrails 28:50 Wearables, records, and the CD-ROM problem 30:07 Rippling - Thanks to our partners at Rippling! Head to https://Rippling.ai/twist and get the only AI built to give you full visibility across your startup and take complex actions across your entire business. 32:51 The wearable that caught Jason's Covid 34:31 Alcohol, sugar, and why almost nobody tests your insulin 40:00 GLP-1s: Jason's 213-to-168 story 42:22 Microdosing GLP-1s, muscle loss, and "skinny fat" 48:48 Overdiagnosing mental illness: SSRIs, Adderall, and a lost decade 50:17 The biology underneath depression and anxiety 54:32 Psychedelics: ketamine, ibogaine, and the second revolution in psychiatry   Subscribe to the TWiST500 newsletter: https://ticker.thisweekinstartups.com Check out the TWIST500: https://www.twist500.com Subscribe to This Week in Startups on Apple: https://rb.gy/v19fcp Follow Lon: X: https://x.com/lons Follow Jason: X: https://twitter.com/Jason LinkedIn: https://www.linkedin.com/in/jasoncalacanis Thank you to our partners: Check out all our partner offers: https://partners.launch.co/ Great TWIST interviews: Will Guidara, Eoghan McCabe, Steve Huffman, Brian Chesky, Bob Moesta, Aaron Levie, Sophia Amoruso, Reid Hoffman, Frank Slootman, Billy McFarland Check out Jason's suite of newsletters: https://substack.com/@calacanis Follow TWiST: Twitter: https://twitter.com/TWiStartups YouTube: https://www.youtube.com/thisweekin Instagram: https://www.instagram.com/thisweekinstartups TikTok: https://www.tiktok.com/@thisweekinstartups Substack: https://twistartups.substack.com

This week we take a step back in time 4 years ago to recall when we spoke with noted cardiovascular surgeon Dr. John J. Lamberti who is Associate Professor of Surgery at Stanford University. Dr. Lamberti's career has spanned from the time of Dr. Robert Gross in the 1960's to present day with Dr. Frank Hanley and the team in Stanford. His career perfectly mirrors the transition from the 'old days' of cardiac surgery up until the present modern age and he shares his reminiscences of working with Dr. Robert Gross, Dr. Aldo Castaneda, Dr. Maurice Lev, Dr. Roberta Williams, Dr. Nadas and others. He also shares his thoughts on how to be a good mentor and what that takes from someone who has mentored many surgeons in the past 5 decades.

Send us Fan MailDr. James J. Thompson is a board-certified cardiovascular radiologist and advanced cardiac imaging specialist with more than 20 years of experience in Cardiac CT Angiography (CCTA) and Cardiac MRI (CMR).He is nationally recognized for expertise in AI-integrated cardiovascular imaging, imaging physics, multimodality diagnostics, radiation optimization, advanced post-processing, and physician education. He has extensive experience collaborating with academic medical centers, national imaging systems, outpatient imaging networks, and emerging cardiovascular AI technologies — developing scalable imaging solutions focused on earlier disease detection, workflow optimization, and improved patient outcomes.Dr. Thompson is known for bridging radiology, cardiology, imaging physics, and artificial intelligence through practical real-world implementation, national physician education, and international faculty leadership.Find Dr. Thompson at-https://preventi.ai/IG- @preventi.aiFind Boundless Body at-myboundlessbody.comBook a session with us here! 

Headliner: As extreme heat settles in, WPLN environmental reporter Caroline Eggers explains how an NPR/Boston University investigation finds Tennessee and other states have severely undercounted heat-related deaths.Newsmaker: Metro Council Member Sandra Sepulveda makes her case for banning right turns at red lights, plus she shares a look at her Hispanic-majority district and the newly opened Mariposa Park.Tastemaker: A trailblazer in both cardiology and country music, Dr. Cleveland Francis tells stories from his new memoir, “Do My Heart Good: My Odyssey Through Country Music, Medicine, and History.”

A lot of the advice about sleep focuses on our "body clock", and making sure you get up at the same time every morning. But if you don't have kids' sport to get to, there is nothing better than a cheeky weekend lie in. And in good news, at a recent conference for the European Society of Cardiology, new research was presented that suggests a solid sleep-in could actually be beneficial. To offer her perspective Jesse is joined by Associate Professor Dr Karyn O'Keeffe from Massey University's Sleep/Wake Research Centre, who has over 25 years of experience in sleep research.

Adham Karim, MD, SBL Interventional Cardiologist talks about how issues such as blockages in the heart, DVT's, varicose veins and pulmonary embolisms are treated with medications and minimally invasive procedures.Send us Fan MailSupport the showSarah Bush Lincoln is a 150-bed, not-for-profit, regional health system  located in East Central Illinois.  Follow us on: Faceboook InstagramLinkedIn

The award-winning singer-songwriter and actress Natalie Imbruglia first hit our screens in the early 1990s, playing the role of Beth Brennan in the Australian soap Neighbours. Her 1997 debut single Torn quickly became a worldwide hit, and she's sold more than 10 million albums. Her latest album, Algorithm, is out later this week. Natalie joins Nuala McGovern to discuss some of its themes – relationship breakups, perfectionism and perimenopause, and what it feels like to be championed by the new generation of pop stars.A new definition of heart attacks could help transform the way women are diagnosed and treated. Experts in the field say women have been 'deprioritised' for decades, but this new global guidance has a new focus on the types of heart attacks experienced by women, and the criteria used to detect them. Professor Nick Mills, British Heart Foundation Professor of Cardiology at the University of Edinburgh, joins Nuala to explain along with Allison Lawson, who had a heart attack two years ago.Between 1949 and 1976, an estimated 250,000 mothers in the UK had their new-born children taken from them through a system involving the state, social workers and religious organisations. A landmark BBC documentary, available now on iPlayer, Stolen Babies, tells the story of those women and the children who were taken from them. In July, the outgoing Prime Minister Sir Keir Starmer issued a formal apology. Judy Baker, who features in the documentary talks about her own experience of giving up a baby.Bestselling author Adele Parks joins us to talk about her new book Eyes On You which follows the story of Amy who, at fifteen, witnessed her father brutally murder his mistress. She tells Nuala why she wanted to explore the effect of such a crime on the perpetrator's family, and how she has tried to make each of her 26 books better than the last.

Cardiovascular disease remains the number one killer of both women and men in the United States. Most of us will need to see a cardiologist or cardiac surgeon at some point in our lives. But, how do you find the best doctor who is right for you? In this episode, three experts representing different subspecialties within cardiovascular health offer advice to patients asking: How do I pick a cardiologist or cardiac surgeon? Jeffrey Kuvin, MD, is executive director and senior vice president of cardiology at Northwell Health. He is also co-executive director of the Northwell Cardiovascular Institute. Alan Hartman, MD, is senior vice president and executive director of cardiovascular and thoracic surgery at Northwell Health. He is also chair of cardiovascular and thoracic surgery at North Shore University Hospital and Long Island Jewish Medical Center. Varinder Singh, MD, is senior vice president of cardiology for Northwell's Metro Market and the Guenther Chair for the Department of Cardiology at Lenox Hill Hospital. Chapters: 00:01 - Intro 01:09 - Who should see a cardiologist? 02:19 - Start with your primary care doctor 03:01 - Is the doctor Able? Affable? Available? 03:29 - Connecting with your doctor 05:38 - Finding the right cardiac surgeon 07:18 - Quality ratings 09:45 - The importance of trust 12:!7 - General vs interventional cardiology 14:14 - What is your vascular age? 15:44 - Why volume matters 17:00 - Does gender play a factor Further references: Learn more about quality ratings for cardiac surgery NYS Department of Health (DOH) 2026 report on adult cardiac surgery US News & World Report rankings Society of Thoracic Surgeons reports Northwell Cardiovascular Institute 2025 Annual Report Northwell is New York State's largest healthcare provider and private employer, with 28 hospitals, 890 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit our career site and explore our many opportunities. Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn.

Join guest Emily Brown, a Cardiovascular Genetic Counselor who has worked with ATTR-CM patients for over a decade. Emily dives into the role of genetic testing in diagnostics and personalized therapies. Emily shares practical strategies and examples of team based care with a multi-disciplinary care team to tackle turning the tide on ATTR-CM. Emily shares suggestions for resources and support for genetic testing for patients.Related PCNA Resources:The Role of Artificial Intelligence in Cardiovascular Care: ATTR Case Study (CE Course) Heart Failure and ATTR-CM: A Guide for Health Care Professionals Hereditary Amyloidosis: What you need to know fact sheet Related Episode Resources:ForgingBridges - Resources to help support you and your patients See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join guest Dana Miller, Advanced HF Nurse Practitioner, to discuss the science and evidence to turn the tide on ATTR. Dana provides an overview of recent clinical trials and how an ATTR-CM diagnosis impacts rate of hospitalization, mortality and quality of life. Dana shares resources and recommendations to continue to learn more about the ever-evolving ATTR-CM treatment and management strategies.Related PCNA Resources:The Role of Artificial Intelligence in Cardiovascular Care: ATTR Case Study (CE Course) Heart Failure and ATTR-CM: A Guide for Health Care Professionals Hereditary Amyloidosis: What you need to know fact sheet Related Episode Resources:CRISPR-Cas9 In Vivo Gene Editing for Transthyretin AmyloidosisTransthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical GuidanceChanging Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort StudyOutcomes in patients with cardiac amyloidosis undergoing catheter ablation for atrial arrhythmiasAmyloidosis Research ConsortiumHeart Failure Society of America (HFSA)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join guest Morgan Lewis, an Amyloid Nurse Clinician, to learn about how ATTR-CM impacts patient's quality of lives. Morgan describes the variants of ATTR-CM as well ad dives into the ongoing unmet needs of patients iwth ATTR-CM. Morgan shares practical examples to overcome challenges to patient care and optimal health outcomes using team-based care strategies.Related PCNA Resources:The Role of Artificial Intelligence in Cardiovascular Care: ATTR Case Study (CE Course)Heart Failure and ATTR-CM: A Guide for Health Care ProfessionalsHereditary Amyloidosis: What you need to know fact sheetSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Listener feedback on mechanical CPR devices, PFA and stroke, the Lindy effect in adopting new technology, and an ESC preview are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback on Mechanical Compression Devices for OHCA   Mechanical CPR Device Use and Cardiac Arrest Survival https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079272 PARAMEDIC trial https://www.thelancet.com/article/S0140-6736(14)61886-9/fulltext CIRC trial https://www.resuscitationjournal.com/article/S0300-9572(14)00128-2/fulltext LINC trial https://jamanetwork.com/journals/jama/fullarticle/1774037 Cochrane Review – Mechanical vs Manual Chest Compressions for Cardiac Arrest https://pmc.ncbi.nlm.nih.gov/articles/PMC6953326/ II PFA and Stroke Risk of Stroke and TIA With PFA vs RF Ablation https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.126.081092 AVANT GUARD Trial https://www.nejm.org/do/10.1056/NEJMdo008538/full/ EMBOL-AF Registry https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag217/8566008 III A New ICD Lead LEADR LBBAP Trial https://doi.org/10.1016/j.hrthm.2026.08.030 IV ESC Preview Mandrola's Preview of the European Society of Cardiology 2026 https://www.medscape.com/viewarticle/mandrolas-preview-european-society-cardiology-2026-2026a1000tfi You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review the use of right axillary artery access for aortic valvuloplasty in infants. Why would this approach potentially offer advantages versus the more traditional femoral or even carotid approach? What are the particular dangers of this approach? How should the interventionist pick the approach when planning an aortic valvuloplasty in an infant with valvar aortic stenosis? We speak with Dr. Jameel Al-Ata of King Faisal Specialist Hospital in Jeddah, Saudi Arabia this week. DOI: 10.1007/s00246-025-03991-6

Should every child be screened for high cholesterol, and what happens afterward? Sadia Malik, M.D., Pediatric Cardiologist at Children's Health and Associate Professor at UT Southwestern, describes the LEAD Initiative and why guidelines recommend a universal lipid check around ages 9–11. Learn more. 

Is fat good or bad for your heart? For decades, we blamed fat and cholesterol for clogged arteries and heart attacks. Now you choose low-fat yogurt to protect your heart, while others cook with beef tallow. In this episode, Dr. Alice Lichtenstein, a world-leading expert on dietary fat and heart health, helps settle the debate. Dr. Lichtenstein explains which fats protect your heart and which to cut back on, you'll learn what raises your cholesterol, and why the type of fat you eat matters more than how much of it you eat. You'll leave the episode with some practical food swaps to protect your heart and live longer. Have you swapped butter for "low-fat" alternatives loaded with sugar? Could that choice be working against your heart?

In this conversation, Dr. Jeffrey Gladden and Dr. Philip Ovadia discuss the critical intersection of cardiology and longevity, emphasizing the need for a shift from treating heart disease to preventing it. They explore personal transformations, the role of diet, particularly low-carb and carnivore diets, and the importance of understanding insulin resistance in relation to heart health. The discussion also highlights advancements in cardiovascular diagnostics and the necessity for early detection and patient education to combat heart disease effectively.   For Audience Join the other 20,000+ high-performers getting weekly insights on biological reversal, exponential strategies, and Life Energy optimization→ https://start.gladdenlongevity.com/subscribe If you're ready to measure your 60+ biological ages and build a personalized reversal plan, apply for a discovery call here → https://start.gladdenlongevity.com/apply-now   Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/!    Takeaways ·       The focus on longevity in cardiology is essential. ·       Preventing heart disease is more effective than treating it. ·       Personal health transformations can lead to professional insights. ·       Dietary changes can significantly impact heart health. ·       Insulin resistance is a major factor in heart disease. ·       Understanding the role of cholesterol is crucial. ·       Early detection of insulin resistance can prevent heart disease. ·       Patient education is vital for long-term health outcomes. ·       Innovative diagnostics can revolutionize heart disease management. ·       A holistic approach to rehabilitation is necessary for recovery.   Chapters 00:00 Introduction to Longevity in Cardiology 02:50 The Shift from Treatment to Prevention 05:59 Personal Transformation and Dietary Changes 08:58 Understanding Insulin Resistance and Heart Disease 12:02 The Role of Diet in Cardiovascular Health 15:07 Innovations in Cardiovascular Diagnostics 18:02 The Importance of Early Detection 20:56 Rehabilitation and Patient Education 24:07 The Future of Cardiology and Preventative Care   To learn more about Dr. Philip Ovadia: Facebook: https://www.facebook.com/ovadiahearthealth Instagram: https://www.instagram.com/ifixhearts/ Twitter: https://twitter.com/ifixhearts X URL: https://x.com/ifixhearts YouTube: https://www.youtube.com/@IFixHearts LinkedIn: Linkedin.com/in/philip-ovadia-heart-health/ Book: https://www.amazon.com/Stay-off-Operating-Table-Metabolic/dp/1737818205/   Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw       Gladden Longevity Podcast Disclosures Production & Independence The Gladden Longevity Podcast and Age Hackers are produced by Gladden Longevity Podcast, which operates independently from Dr. Jeffrey Gladden's clinical practice and research at Gladden Longevity in Irving, Texas. Dr. Gladden may serve as a founder, advisor, or investor in select health, wellness, or longevity-related ventures. These may occasionally be referenced in podcast discussions when relevant to educational topics. Any such mentions are for informational purposes only and do not constitute endorsements. Medical Disclaimer The Gladden Longevity Podcast is intended for educational and informational purposes only. It does not constitute the practice of medicine, nursing, or other professional healthcare services — including the giving of medical advice — and no doctor–patient relationship is formed through this podcast or its associated content. The information shared on this podcast, including opinions, research discussions, and referenced materials, is not intended to replace or serve as a substitute for professional medical advice, diagnosis, or treatment. Listeners should not disregard or delay seeking medical advice for any condition they may have. Always seek the guidance of a qualified healthcare professional regarding any questions or concerns about your health, medical conditions, or treatment options. Use of information from this podcast and any linked materials is at the listener's own risk. Podcast Guest Disclosures Guests on the Gladden Longevity Podcast may hold financial interests, advisory roles, or ownership stakes in companies, products, or services discussed during their appearance. The views expressed by guests are their own and do not necessarily reflect the opinions or positions of Gladden Longevity, Dr. Jeffrey Gladden, or the production team. Sponsorships & Affiliate Disclosures To support the creation of high-quality educational content, the Gladden Longevity Podcast may include paid sponsorships or affiliate partnerships. Any such partnerships will be clearly identified during episodes or noted in the accompanying show notes. We may receive compensation through affiliate links or sponsorship agreements when products or services are mentioned on the show. However, these partnerships do not influence the opinions, recommendations, or clinical integrity of the information presented. Additional Note on Content Integrity All content is carefully curated to align with our mission of promoting science-based, ethical, and responsible approaches to health, wellness, and longevity. We strive to maintain the highest standards of transparency and educational value in all our communications.

In this MedAxiom HeartTalk, host Melanie Lawson, MS, talks with Jacob Corbell, MBA, CEO of Midwest Cardiovascular Institute, about the administrative strain pulling time away from patient care. Corbell shares how partnering with Basata helped his team cut call abandonment to 1% and reduce hold times to under 30 seconds. He also explains why the real opportunity is not replacing staff but freeing them to do more meaningful work. It's a practical look at where AI is already making a difference and where it could go next.

Cardiovascular disease remains a leading cause of death, while evolving guidelines and increasingly aggressive LDL cholesterol targets are changing how clinicians approach lipid management. Jodi Martinez, Pharmacist Clinical Specialist in Cardiology at the University of Colorado Hospital, part of UCHealth, joins Kerry Schwarz, Senior Clinical Manager for Evidence Based Medicine and Outcomes with the Vizient Center for Pharmacy Practice Excellence, to explore the emerging role of enlicitide in lipid management. They discuss the evidence behind its approval, its potential to expand patient access and where this first oral PCSK9 inhibitor may fit alongside existing therapies.   Guest Speaker: Dr. Jodi Martinez, Pharm.D., BCPS, BCCP, HF-CERT Pharmacist Clinical Specialist in Cardiology University of Colorado Hospital, UCHealth   Host:  Dr. Kerry Schwarz, Pharm.D., MPH Senior Clinical Manager, Evidence-Based Medicine and Outcomes Vizient Center for Pharmacy Practice Excellence    Show Notes:  [01:26] The limitations of current lipid management and why many high-risk patients still struggle to reach increasingly aggressive LDL cholesterol targets. How cost, prior authorization requirements and step therapy can create barriers to accessing injectable PCSK9 therapies. [03:27] The evidence behind enlicitide and findings from the CORALreef clinical trial supporting its FDA approval. How enlicitide performed across LDL cholesterol, non-HDL cholesterol, ApoB and lipoprotein(a) endpoints, and why cardiovascular outcomes remain an important unanswered question. [06:37] An oral PCSK9 inhibitor could expand access by offering an alternative to specialty injectable therapies. Why retail pharmacy availability, cost and greater prescribing flexibility could help more patients receive intensive lipid lowering therapy. [08:11] The potential barriers to enlicitide adoption, including delays in formulary review, insurance coverage and the administrative burden placed on clinicians. The lack of published cardiovascular outcomes could influence payer coverage, formulary placement and early uptake. [10:15] Station remains the cornerstone of lipid management and where enlicitide may ultimately play a role Clinicians may consider the amount of LDL reduction a patient needs when choosing among available therapies.   Links and Resources: 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed    

Mechanical CPR devices, the dangers of AF performance measures, two scholarly articles on CLOSURE and CHAMPION, and a little ESC preview are the topics John Mandrola, MD, discusses in this week's podcast.  This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Mechanical Compression Devices for OHCA ·       Mechanical CPR Device Use Cardiac Arrest Survival https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079272 ·       PARAMEDIC Trial https://www.thelancet.com/article/S0140-6736(14)61886-9/fulltext ·       CIRC Trial https://www.resuscitationjournal.com/article/S0300-9572(14)00128-2/fulltext ·       LINC trial https://jamanetwork.com/journals/jama/fullarticle/1774037 ·       Cochrane Review of Mechanical vs Manual Chest Compressions for Cardiac Arrest  https://pmc.ncbi.nlm.nih.gov/articles/PMC6953326/ II ACC AF Performance Measures ·       2026 AHA/ACC Clinical Performance for Patients With AF https://www.jacc.org/doi/10.1016/j.jacc.2026.05.032#sec-3 III Two Critical Appraisals of the recent LAAC trials ·       Reappraising CHAMPION-AF 10.1016/j.hrthm.2026.07.048 External Link ·       CHAMPION and CLOSURE: Reconciling Contrast Results https://doi.org/10.1093/eurheartj/ehag608 ESC Early Preview ·       CMR Guide trial https://pmc.ncbi.nlm.nih.gov/articles/PMC6931571/ ·       SINGLE AF Trial 10.1016/j.hroo.2025.12.008 External Link  You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

How much time do you spend looking at a screen when you'd rather be making eye contact with your patient? In this MedAxiom HeartTalk, R. Kannan Mutharasan, MD, MBA, FACC, FAHA, cardiologist at Northwestern Medicine, shares how AI is helping clinicians stay focused on patients and uncover insights that could lead to earlier diagnoses. As the technology advances, the real work of realizing AI's potential in everyday cardiovascular care is just beginning.

In this session, attendees will be equipped to navigate the discernment process of identifying the best-fit sending agency for them.

What is a nurse scientist, and what is the difference between one that is PhD-prepared versus DNP-prepared? Guest Dawn Aycock, PhD, RN, ANP-BC, FAHA, FPCNA, FAAN, shares about the importance of nurse engagement in research, and how to get involved, no matter your role or location.Related PCNA Resources:Presenting Your Work: Call for Abstracts: https://pcna.net/events-news/cardiovascular-nursing-symposium/call-for-abstracts/Empowering CV Nurses to Engage in Clinical Research (article): https://pcna.net/news/empowering-cardiovascular-nurses-to-engage-in-clinical-research/Clinical Research: Engaging with the Community (podcast): https://pcna.net/podcast/clinical-research-engaging-with-the-community/About Research and Evidence-Based Practice (article): https://pcna.net/health-topics/research-and-evidence-based-practice/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For new graduates of nurse practitioner programs, cardiovascular-focused knowledge and skills can be improved with additional professional development opportunities. Guest Michelle Alland, APRN, AGACNP-BC, MSN, FNP-C, AACC, describes postgraduate fellowships, local and national training options, onboarding, and the importance of mentorship from more tenured NPs.RELATED PCNA RESOURCES:Professional DevelopmentAwardsAbstractsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Listener feedback, the ZEUS trial fails, a fascinating statin trial, more on GLP-1 drugs, and radiation safety in the EP lab are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I ZEUS Fails Rethinking Inflammation and ASCVD: Four Lessons From the ZEUS Trial https://www.medscape.com/viewarticle/rethinking-inflammation-and-ascvd-four-lessons-zeus-trial-2026a1000rlm ZEUS Trial https://doi.org/10.1001/jamacardio.2025.4491 II Statins and the Elderly SAGA/SITE trial 10.1016/j.lanhl.2026.100884 External Link III GLP-1 and CV Risk SURMOUNT-1 Trial https://www.nejm.org/doi/10.1056/NEJMoa2206038 SURMOUNT-1 Post Hoc Analysis https://www.jacc.org/doi/10.1016/j.jacc.2026.04.044 Reframing GLP-1s as Cardiometabolic Health Drugs: Editorial https://www.jacc.org/doi/10.1016/j.jacc.2026.06.039 IV Radiation Exposure to the Uterus in the EP Lab Occupational Radiation Safety in EP During Pregnancy https://www.ahajournals.org/doi/epub/10.1161/CIRCULATIONAHA.126.080556 Survey: Working in Cath Lab During Pregnancy https://www.surveymonkey.com/share/d5c1edf7-6d99-49d4-a9fa-e9168f63ab55 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we speak with Dr. Ted O'Leary, Co-Director of Adult Congenital Heart Disease Electrophysiology at Boston Children's Hospital about a recent publication he authored on the use of pulsed field ablation (PFA) for the transcatheter ablation management of complex atrial arrhythmias in ACHD patients. How does PFA work and what are some of the potential advantages and disadvantages of this novel ablation energy technology? What are the advantages of a variable loop catheter in this setting? Is PFA going to supplant radiofrequency current for standard "SVT" ablations one day? These are amongst the questions reviewed with Dr. O'Leary this week. DOI: 10.1161/CIRCEP.125.014619

In this episode of MedAxiom HeartTalk, host Melanie Lawson, MS speaks with Byron Lee, MD, professor of medicine and cardiology at Stanford, about the growing importance of remote cardiac monitoring in patient care. Dr. Lee shares how extended 30-day monitoring helps improves arrhythmia detection and guides long-term treatment. He also discusses how real-time data transmission and streamlined reporting allow care teams to identify and address serious cardiac events more quickly and confidently.

CardioNerds (Dr. Apoorva Gangavelli, Dr. Rebecca Garber, and Dr. Tina Reddy), discuss pre-pregnancy risk stratification and counseling with Dr. Katy Young across a range of risks.  This episode was produced as part of the CardioNerds Academy curriculum by House Einthoven under the guidance of House Chief, Dr. Apoorva Gangavelli and Academy Program Director, Dr. Gurleen Kaur. A matching review article will be published in US Cardiology Review, the official journal of CardioNerds. This discussion was planned in collaboration with the Mayo Clinic Cardiovascular Board Review Course. Audio editing by CardioNerds intern, Dr. Patrick Pekyi-Boateng. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Notes:  Why is pregnancy considered a “physiologic stress test,” and why does risk extend beyond delivery? Blood volume, heart rate, and cardiac output rise while systemic vascular resistance falls, peaking in the late second/early third trimester; underlying (even undiagnosed) heart disease can be unmasked or worsened. Postpartum (“fourth trimester”) is a high-risk period, not a safe zone – fluid shifts, rising SVR, and bleeding risk can precipitate decompensation in patients with heart failure, pulmonary hypertension, valvular disease, or aortopathy. Adverse pregnancy outcomes (hypertensive disorders, gestational diabetes, preterm birth, fetal growth restriction, peripartum cardiomyopathy) are markers of future cardiovascular risk and warrant long-term preventive follow-up. What is the practical framework for approaching pre-pregnancy cardiovascular risk? Four broad categories: (1) patients who may need cardiac screening before pregnancy, (2) patients needing risk-factor/medication optimization, (3) known cardiovascular disease where pregnancy is reasonable with structured risk stratification, and (4) high-risk disease where pregnancy may need to be delayed, modified by intervention, or discouraged. Testing should be targeted, not blanket – reserved for symptoms, abnormal exam, concerning family history, or reduced functional capacity. How is risk stratified in patients with known cardiovascular disease? Use a combination of tools per 2025 ESC guidelines: mWHO 2.0 (broad maternal risk category), CARPREG II (additional predictors of maternal cardiac events), and ZAHARA (useful in congenital heart disease). Key lesion-specific factors: aortic size/growth, valve severity, ventricular function, symptoms, blood pressure, and family history of dissection. Translate risk into practical terms for patients rather than leading with a numerical score. Which cardiovascular medications require review before conception? ACE inhibitors, ARBs, and ARNIs should be transitioned off before pregnancy; statins, MRAs, and SGLT2 inhibitors also need review. DOACs are contraindicated in pregnancy and lactation; mechanical valve anticoagulation requires individualized shared decision-making, as no strategy is risk-free for mother and fetus. Medication changes are best made proactively, before conception, rather than reactively. This is not an exhaustive list! The medication list needs to be reviewed carefully. Which conditions carry high or prohibitive risk in pregnancy? Pulmonary arterial hypertension, Eisenmenger syndrome, severe ventricular dysfunction, prior peripartum cardiomyopathy with residual LV dysfunction, severe left-sided obstructive valve disease (e.g., severe mitral stenosis), mechanical valves, significant aortopathy, cyanotic congenital heart disease, and Fontan physiology. Common theme: limited cardiovascular reserve and high risk of decompensation, thrombosis, arrhythmia, heart failure, aortic dissection, or death. These patients need expert multidisciplinary evaluation before pregnancy. Severe mitral stenosis is poorly tolerated because tachycardia shortens diastolic filling time and raises left atrial pressure, risking pulmonary edema and decompensation. When should genetic testing or counseling be offered? Consider when a diagnosis may be inherited or affect the patient, pregnancy, or family members: inherited cardiomyopathies, aortopathies, channelopathies, select congenital heart disease, and some pulmonary hypertension syndromes. Recurrence risk of congenital heart disease in offspring is roughly 6-10% when the mother has CHD; fetal echocardiography should be offered. How should contraception be approached in high-risk cardiac patients? Frame contraception as part of the cardiac care and reproductive safety plan to prevent unplanned high-risk pregnancy. Long-acting reversible contraception is often preferred; progestin-only methods are generally safer than estrogen-containing options with thrombosis risk, pulmonary hypertension, or mechanical valves. What are key delivery-planning considerations for cardiac patients? Vaginal delivery is preferred unless there is an obstetric indication for cesarean or a specific cardiac reason (e.g., unstable maternal status, therapeutic INR) to avoid labor. Planning should address delivery location, anesthesia involvement, telemetry needs, fluid management, and postpartum monitoring, clearly communicated across the multidisciplinary team in advance. How should clinicians counsel patients when pregnancy is discouraged but strongly desired? Acknowledge the patient’s goals and the emotional weight of the conversation; separate the goal (family building) from the timeline (safety now vs. after optimization). If pregnancy remains prohibitively risky, discuss alternatives for family building and ensure adequate patient support. What are the key gaps and future directions in cardio-obstetric risk stratification? Current risk tools (mWHO, CARPREG II, ZAHARA) provide common language but do not fully capture functional status, prior pregnancy history, or how risk evolves over time. Future direction: individualized, dynamic risk prediction incorporating imaging, biomarkers, exercise capacity, and social drivers of health, with better long-term links between pregnancy complications and cardiovascular prevention. References 1. European Society of Cardiology. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. 2. Mehta LS, et al. Cardiovascular Considerations in Caring for Pregnant Patients: A Scientific Statement From the American Heart Association. Circulation. 2020;141:e884-e903. PMID: 32362133. doi:https://doi.org/10.1161/CIR.0000000000000772 3. ACOG Practice Bulletin No. 212. Pregnancy and Heart Disease. Obstet Gynecol. 2019;133(5):e320-e356. PMID: 31022123. doi:https://doi.org/10.1097/AOG.0000000000003243

Parents often assume their teen's school counselor can handle every part of the college planning process, but the reality is far more collaborative.In this episode, Lisa Marker-Robbins and Stephanie Simpson, CEO of the Independent Educational Consultants Association (IECA), explore how the right team and a foundation of self-awareness can help students make thoughtful college decisions.In this episode, Lisa and Stephanie discuss:How school counselors, independent educational consultants, and families each contribute to college planningWhy self-awareness should guide college and career decisions from the startWhen outside college planning support can benefit students and familiesWhat to consider when choosing an independent educational consultantKey Takeaways: Start career and identity exploration before college applications so students make decisions based on who they are, not deadlines.Independent educational consultants help students present their authentic story and find the right college fit, not improve their admissions odds.Many begin in junior year; starting by sophomore year creates more time for thoughtful course selection, extracurriculars, and summer opportunities.Choose an independent educational consultant whose expertise matches your student's needs and complements the school counselor's support. “Independent means that these counselors do not receive any compensation from a program, school, or university to place or recommend a student, so they really can provide that unbiased advice.” – Stephanie SimpsonAbout Stephanie Simpson: Stephanie Simpson is the Chief Executive Officer of IECA, the leading professional organization for independent educational consultants supporting students and families through college and career planning. Previously, she led the Association for Middle Level Education (AMLE) and held senior leadership roles at the American College of Cardiology and the American Psychiatric Association. She holds a JD from Northwestern University Pritzker School of Law and a BA from DePaul University.Episode References:Learn more about Launch Career Clarity at https://flourishcoachingco.com/courseFind a Private College Counselor: https://www.iecaonline.com/independent-educational-consultant-search/#230 Stop Trying to Impress Colleges: What Admissions Really Want with Susan Knoppow: https://flourishcoachingco.com/230Get Lisa's Free on-demand video: THE CAREER IDENTIFICATION COMPASS: How To Be Certain Your 15 To 25 Year Old is On The Right Path to Launch With Confidence–Not Confusion: flourishcoachingco.com/video Connect with Stephanie:Website: https://www.iecaonline.com/LinkedIn: https://www.linkedin.com/in/stephanie-simpson-49bba72a/Connect with Lisa:Website: https://www.flourishcoachingco.com/YouTube: https://www.youtube.com/@flourishcoachingcoFacebook: https://www.facebook.com/flourishcoachingco/ Instagram: https://www.instagram.com/flourishcoachingco/LinkedIn: https://www.linkedin.com/company/flourish-coaching-co

In this insightful episode of Parallax, Dr Ankur Kalra is joined by Dr Barry Borlaug, Professor of Cardiology at Mayo Clinic and one of the world's leading experts in cardiac haemodynamics, for a comprehensive discussion on the evolving landscape of heart failure with preserved ejection fraction (HFpEF). Together, they explore the complexities of diagnosing and managing a syndrome that continues to challenge clinicians. Dr Borlaug explains why exercise right-heart catheterisation remains the gold standard for uncovering "hidden" HFpEF, particularly in patients with normal resting filling pressures, and provides a detailed overview of the Mayo Clinic's invasive exercise testing protocol. The conversation also traces the evolution of HFpEF phenotyping, from the traditional hypertensive patient to the increasingly recognised obesity-driven phenotype, highlighting the role of systemic inflammation, visceral adiposity and disease progression across the HFpEF spectrum. Dr Borlaug outlines what he describes as the modern therapeutic backbone for HFpEF in 2026, reviewing the evidence supporting SGLT2 inhibitors, mineralocorticoid receptor antagonists including finerenone, and incretin-based therapies such as semaglutide and tirzepatide. Looking ahead, he discusses emerging investigational approaches including sotatercept, the challenges facing device-based therapies, and the importance of identifying HFpEF mimics such as cardiac amyloidosis and hypertrophic cardiomyopathy to ensure patients receive the most appropriate treatment. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: American healthcare is at a crossroads, and the decisions we make now will define the health of generations to come.Dr. Marschall Runge has spent more than four decades at the center of that challenge, serving as former CEO of Michigan Medicine, Dean of the University of Michigan Medical School, and EVP for Medical Affairs.A practicing cardiologist trained at Johns Hopkins and Massachusetts General Hospital, Dr. Runge brings both the scientist's rigor and the leader's vision to one of the most urgent conversations of our time.In his Amazon and USA Today bestselling book, "The Great Healthcare Disruption," he lays out a bold prescription for reimagining American medicine through AI, innovation, and courageous systemic change.Join us to discover what it truly takes to transform healthcare from the inside out. Let's go!Episode Highlights:Dr. Runge never planned to be a CEO, initially dismissing healthcare leaders before serendipity shaped his path.His personal hospital-at-home experience after hip surgery confirmed that recovery is faster, cheaper, and better at home.Ambient AI, which auto-generates clinical notes, is the one decision at Michigan Medicine that faced almost no dissent.America's top-tier quaternary care leads the world; the real crisis is access, not quality.AI can address the clinician shortage in a year or two, something traditional training pipelines need decades to solve.About our Guest:Marschall S. Runge, M.D., Ph.D., was born in Austin, Texas, and graduated from Vanderbilt University with a BA in General Biology and a PhD in Molecular Biology. He received his medical degree from the Johns Hopkins School of Medicine and trained in internal medicine at Johns Hopkins Hospital. He was a cardiology fellow and junior faculty member at Massachusetts General Hospital. Dr. Runge's next position was at Emory University, where he directed the Cardiology Fellowship Training Program. He then moved to the University of Texas Medical Branch in Galveston, where he was Chief of Cardiology and Director of the Sealy Center for Molecular Cardiology. He joined the University of North Carolina (UNC) from 2000 – 2014, where he served as Charles Addison and Elizabeth Ann Sanders Distinguished Professor of Medicine, Chair of the Department of Medicine, President of UNC Physicians and Vice Dean for Clinical Affairs.Dr. Runge is the former CEO of Michigan Medicine and Dean of the University of Michigan Medical School, and a practicing cardiologist. Dr. Runge is board-certified in internal medicine and cardiovascular diseases and has spoken and published widely on topics in clinical cardiology and vascular medicine.At the University of Michigan, Dr. Runge began serving as the executive vice president for medical affairs in March 2015 and, in January 2016, he was also appointed as the dean of the Medical School. He is the first person to serve in this combined position created by the Regents for the purpose of strengthening the integration between the Medical School and health care delivery in our hospitals and health centers.During his tenure in these leadership roles, Dr. Runge has implemented transformative change and positioned Michigan Medicine and the Medical School for continued success. Notable achievements during this period include: a significant expansion of Michigan Medicine's clinical network in the state, through integration of two health systems, the former Metro Health in Grand Rapids and Sparrow Health System in Lansing, multiple joint ventures with Trinity Health, launch of the Precision Health Initiative, a major research collaboration with several other U-M schools and colleges; oversight of the conclusion of the Victors for Michigan campaign which raised $1.5 billion dollars for institutional strategic priorities; and the development and implementation of Michigan Medicine's first strategic plan for diversity, equity and inclusion in support of the broader university-wide DEI initiative.Under Dr. Runge's leadership, the University of Michigan Health's adult hospitals were ranked best in Michigan in 2023-2024 in U.S. News & World Report “Best Hospitals” rankings, the 31st consecutive year that U-M Health has been nationally recognized for strong across-the-board performance. In Newsweek's 2024 ranking of America's Best Hospitals, U-M Health ranked #1 in the state and #3 in the country.Current and new initiatives under Dr. Runge's leadership include construction of the The D. Dan and Betty Kahn Health Care Pavilion, a 12-story and 264 private room inpatient hospital; working to reduce faculty and staff burnout; executive rounding to help promote employee engagement and retention; establishment of the Heart Brain Institute and Global Health; oversight and development of the Anti-Racism Oversight Committee to help achieve an anti-racist culture; improved access and patient experience through the M2C2 Capacity Center; and the establishment of the Care at Home initiative which focuses on providing safe, hospital-level care to patients in their own home.Dr. Runge has been a physician-scientist for his entire career, combining basic and translational research with the care of patients with cardiovascular diseases and education. He is the author of over 200 publications in the field and holds five patents for novel approaches in health care.Links Supporting This Episode: Dr. Marschall Runge Website: CLICK HEREDr. Marschall Runge LinkedIn page: CLICK HEREThe Great Healthcare Disruption book link: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: CLICK HERE

This week's replay episode reviews the notion of the underrepresented in medicine physician and the decision to pursue pediatric cardiology. How would improved representation amongst the congenital heart work force result in better outcomes for patients? How does a diverse workforce foster improved communication with patients? What are some practical steps that can be employed to improve representation in the field? We speak with  Dr. Ogochuckwu M Ezeoke Cox, MD of U. Mass about recent essay on this vital topic.https://doi.org/10.1007/s00246-023-03144-7

We have another classic episode for you. Level up your primary prevention game. Learn when ApoB, Lp(a), and CAC actually change management, how to spot cardiometabolic risk before diabetes declares itself, and how to make smarter lipid decisions beyond the standard panel. We're joined by Dr. Greg Katz, cardiologist and prevention expert at NYU Langone Health.

Another failure of LA posterior wall isolation, first-line AF ablation, a revelation on EAST-AFNET 4 trial, an LAAC meta-analysis, and preventing AKI post-cardiac surgery are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588 II Another Failure of Posterior Wall Isolation CORNERSTONE-AF Trial https://doi.org/10.1093/eurheartj/ehag486 CAPLA Trial https://jamanetwork.com/journals/jama/fullarticle/2800186 PVIOTAL IDE Trial 10.1016/j.hrthm.2025.08.018 External Link III First Line AF ablation – One new study and a discovery about a second one Catheter Ablation vs AAD for First-line Treatment of AF 10.1016/j.hrthm.2025.07.061 External Link EAST-AFNET 4 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2019422 Cardiology Trials Substack https://cardiologytrials.substack.com/p/summary-and-discussion-of-east-afnet IV Left Atrial Appendage Closure Meta-analysis Long-Term Efficacy and Safety of LAAC vs OAC -- Meta-analysis https://academic.oup.com/europace/article/28/7/euag159/8739567 V Prevention of AKI after Cardiac Surgery: MERCURI-2 MERCURI-2 Study https://jamanetwork.com/journals/jama/fullarticle/2852324 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This week we review a recent book entitled Reimagining a Child's Heart: The Lone Pines of Congenital Cardiology which was recently published by Springer and which was authored by Dr. Thomas J. Kulik and Dr. Macdonald Dick. Drs. Kulik and Dick recount the innumerable steps in discovery that led to what the authors view as one of the pinnacles of achievement in our field, namely the palliation of children with HLHS and single ventricle disease. Dr. Kulik tragically passed suddenly in 2021 but his friend and colleague Dr. Dick completed the book that Dr. Kulik had spent over a decade toiling over. This week we sit down with Dr. Dick and also, briefly, Dr. Roberta Williams and Dr. Kulik's wife Ms. Linda Kulik to discuss the book, Dr. Kulik's legacy, mentorship and more. Dr. Dick also shares with us what he believes are the keys to a successful retirement. This is a rare opportunity to listen to some of the truest pioneers of our field, 'Lone Pines" themselves share their insights and warm stories. For those interested, this is one of many sites to obtain the book:https://www.amazon.com/dp/3031886070?lv=shuf&channelId=500&plpRedirect=mhFallbackAlso mentioned in this episode are 2 prior episodes including our conversation with Dr. Michael Freed and our conversation with Ms. Patricia Meisol and links are below:https://podcasts.apple.com/us/podcast/pediheart-podcast-203-a-conversation-with-dr-michael-freed/id1341472214?i=1000556610155https://podcasts.apple.com/us/podcast/pediheart-podcast-320-the-extraordinary-life/id1341472214?i=1000677938143

Dr. Philip Ovadia, MD, is a board-certified heart surgeon who became a leading advocate for metabolic health after confronting both his patients' outcomes and his own struggle with obesity and insulin resistance. With decades of surgical experience, he has witnessed firsthand the consequences of metabolic disease. Today, he focuses on prevention, education, and empowering individuals to reverse metabolic dysfunction before surgery becomes necessary. Founder of Ovadia Heart Health and host of The Stay Off My Operating Table Podcast. BUY THE BOOK!  Stay Off My Kitchen Table can be purchased here: https://stayoffmykitchentable.com/ Instagram: https://www.instagram.com/ifixhearts/ Facebook: https://www.facebook.com/ifixhearts YouTube: https://www.youtube.com/@UCu8xppo0Y7mJz4uqkc7o7TQ  Apple Podcasts: https://podcasts.apple.com/ca/podcast/stay-off-my-operating-table/id1587212660 Timestamps: 00:00 Trailer 01:11 Introduction 03:27 Interest in cardiac surgery and metabolic health 07:35 Healthcare system restrictions on doctors 12:31 Cardiac diet and post-surgery care 15:28 Book release and diet exploration 19:54 Moving to Florida and health insights 22:53 Controversial PCSK9 trial results 26:09 Challenges in understanding cholesterol 30:19 Discussing heart disease diagnoses 31:33 Importance of arterial plaque screening 37:26 Heart attacks and undiagnosed diabetes 39:13 Understanding CAC score progression 44:38 Discussing blood pressure guidelines 46:40 Where to find Dr. Ovadia Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

The first oral PCSK9 inhibitor, another study finding safe MRI scanning in patients with nonconditional CIEDs, the PFA-SHAM trial, and the curious case of orthopedic injuries in cardiology are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic   I Enlicitide Approved First Oral PCSK9 Inhibitor Welcomed for Potential Primary Care Impact https://www.medscape.com/viewarticle/first-oral-pcsk9-inhibitor-welcomed-potential-primary-care-2026a1000own Dr Gregory Katz Substack https://gregorykatz.substack.com/p/are-we-sure-mercks-new-cholesterol CORALreef Lipids Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002 CORALreef HeFH Trial https://jamanetwork.com/journals/jama/fullarticle/2841258 CORALreef Outcomes Trial https://clinicaltrials.gov/study/NCT06008756 II MRI Scans in Non-conditional CIEDs Specialized Nurse Practitioners Safely Manage MRI in Patients With Cardiac Implantable Devices https://www.medscape.com/viewarticle/specialized-nurse-practitioners-safely-manage-mri-patients-2026a1000ozt Nurse Practitioner-Led CIED Monitoring During MRI 10.1016/j.hroo.2026.04.031 External Link MRI in Nonconditional Pacemakers and ICDs https://academic.oup.com/europace/article/22/2/288/5717383 Heart Rhythm Society Consensus Document 10.1016/j.hrthm.2017.04.025 External Link III PFA-SHAM trial PFA-SHAM Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079484 SHAM-PVI Trial https://jamanetwork.com/journals/jama/fullarticle/2823283 IV Orthopedic Injuries in Cardiology What Will It Take to Make Fluoroscopy Labs Safer? https://www.medscape.com/viewarticle/what-will-it-take-make-fluoroscopy-labs-safer-2026a1000ox6 Expert Consensus Statement on Enhanced Radiation Protection https://www.jacc.org/doi/10.1016/j.jcin.2026.06.011 'Shed the Lead' and the Injuries. Should Cath Labs Go Lead-Free? https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb Health Hazards of Working in the Interventional Laboratory https://doi.org/10.1016/j.jacc.2014.11.056 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net